Exhibit & Support

Exhibitor Directory

Exhibitor Floor Plan


Product Theaters

These sessions are not a part of the official AGS 2022 Annual Meeting Education Program and do not offer CME credit.

Thursday, May 12th from 12:45 PM – 1:30 PM
Exhibit Hall: Atlantic Hall A
Hosted By Urovant

Discover The Impact of Gemtesa, An Effective OAB Treatment: A Fresh Look In Oab Management In Long-Term Care Settings 
The mainstay of OAB Treatment is the class of anticholinergics; these medications are on the BEERS list and recently have become known for their associated risk of cognitive impairment, dementia and AD. Vibegron, a beta-3-adrenergic agonist, is as equally efficacious as the anticholinergic class and has a favorable safety profile 

Learning objectives: 
•    Review OAB, identify different types of urinary incontinence, and explain the burden on the LTC community 
•    Identify residents that have OAB and may benefit from treatment 
•    Compare the pharmacology, efficacy, and safety of OAB treatment options between the anticholinergic and beta-3- adrenergic classes and within the beta-3-adrenergic class
•    Demonstrate understanding of vibegron efficacy and safety data (Phase2b, Phase 3, EMPOWUR, EMPOWUR extension study)

Meenakshi Patel, MD, FACP, MMM, CMD 
Clinical Associate Professor, Wright State University 
Dayton, Ohio

Laurence M. Petty, MD, CMD
Community Preceptor, University of South Florida
Tampa, FL

Friday, May 13th from 12:45 PM – 1:30 PM
Exhibit Hall: Atlantic Hall A

Hosted by Seqirus

A Closer Look at Adjuvanted Vaccines: Preventing Seasonal Influenza in Older Adults 
Older adults (≥ 65 years of age) are especially at risk of morbidity and mortality from seasonal influenza, and annual vaccination is recommended as their best defense. The adjuvanted influenza vaccine has been specifically developed for use in this age group. This presentation will focus on methods to evaluate seasonal influenza vaccine effectiveness and will take a closer look at multiple seasons of vaccine effectiveness data available for adjuvanted influenza vaccines in those 65 years of age and older.

Learning Objectives:
•    Describe the clinical burden of seasonal influenza in older adults
•    Understand the benefits of routine influenza vaccination
•    Review clinical data for Adjuvanted Seasonal Influenza Vaccine in adults (≥ 65 years of age)

Kevin W. Cleveland, PharmD, ANP 
Associate Professor, Pharmacy Practice ISU Kasiska Division of Health Sciences College of Pharmacy 
Meridian, Idaho